Comparison · NCT01222286-2632acdb
IPH2101 0.2 mg/kg vs IPH2101 2 mg/kg: Rate of Patients Achieving an Objective Response
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. IPH2101 0.2 mg/kg vs IPH2101 2 mg/kg: Rate of Patients Achieving an Objective Response. Trial comparisons, record NCT01222286-2632acdb. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01222286-2632acdb
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0 | 0 | 0.194 | wilson | |
| Risk in group 2 | 0 | 0.0000000000000000139 | 0.215 | wilson | |
| Risk difference, group 1 minus group 2 | 0 | -0.215 | 0.194 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | log | a group has no participants with the outcome | |||
| Odds ratio, group 1 over group 2 | log | a cell of the two-by-two table is zero | |||
| Number needed to treat | from the risk difference interval | the two groups' risks are equal |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | IPH2101 0.2 mg/kg | 0.2 mg/Kg every 4 weeks by intravenous route over 1 hour, for 6 or up to 12 cycles | 0 | 16 | OG000 |
| Group 2 | IPH2101 2 mg/kg | 2 mg/Kg every 4 weeks by intravenous route over 1 hour, for 6 or up to 12 cycles | 0 | 14 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Rate of Patients Achieving an Objective Response
- Description
The primary end point is the rate of patients achieving an objective response (defined according to the International Myeloma Working Group uniform response criteria), including minimal response, (as derived from the European Society for Blood and Marrow Transplantation criteria), achieved at any time until end of study and confirmed on two consecutive assessments at 4 weeks interval.
- Time frame
- from start to end of study (14 months)
- Population
- The ITT population included all randomized subjects.
Source ClinicalTrials.gov
Trial
- Title
- Study on the Anti-tumor Activity, Safety and Pharmacology of IPH2101 in Patients With Smoldering Multiple Myeloma
- NCT number
- NCT01222286
- Phases
- PHASE2
- Conditions
- Smoldering Multiple Myeloma
- Interventions
- IPH2101
- Lead sponsor
- Innate Pharma
- Results first posted
- 2014-05-09
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01222286?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01222286-2632acdb